Naldemedine
Medication used in the treatment of Opioid-Induced Constipation / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Naldemedine?
Summarize this article for a 10 year old
Naldemedine (brand name Symproic in the US and Rizmoic in the European Union) is a medication that is used for the treatment of opioid-induced constipation in adults with chronic non-cancer pain. It is a peripherally acting μ-opioid receptor antagonist and was developed by Shionogi.[1] Clinical studies have found it to possess statistically significant effectiveness for these indications and to be generally well tolerated, with predominantly mild to moderate gastrointestinal side effects.[2] Effects indicative of central opioid withdrawal or impact on the analgesic or miotic effects of co-administered opioids have only been observed in a small number of patients.[3]
Clinical data | |
---|---|
Trade names | Symproic, Rizmoic |
Other names | S-297,995 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a617031 |
License data |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 93–94% |
Metabolism | primarily CYP3A4 |
Elimination half-life | 11 hrs |
Excretion | Urine, feces |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C32H34N4O6 |
Molar mass | 570.646 g·mol−1 |
3D model (JSmol) | |
| |
|